The blood-saving effect of tranexamic acid in minimally invasive total knee replacement: is an additional pre-operative injection effective?
Tranexamic acid (TEA), an inhibitor of fibrinolysis, reduces blood loss after routine total knee replacement (TKR). However, controversy persists regarding the dosage and timing of administration of this drug during surgery. We performed a prospective randomised controlled study to examine the optimum blood-saving effect of TEA in minimally invasive TKR. We randomly assigned 151 patients who underwent unilateral minimally invasive TKR to three groups: 1) a placebo group (50 patients); 2) a one-dose TEA group (52 patients), who received one injection of TEA (10 mg/kg) intra-operatively on deflation of the tourniquet; and 3) a two-dose TEA group (49 patients), who received two injections of TEA (10 mg/kg) given pre-operatively and intra-operatively. Total blood loss was calculated from the maximum loss of haemoglobin. All patients were followed clinically for the presence of venous thromboembolism (VTE). The mean total blood loss was significantly higher in the placebo group than in the other two groups (1222 ml (845 to 2043) versus 1035 ml (397 to 1934) and 986 ml (542 to 1811), respectively (both p < 0.0001)). The mean blood loss was not significantly different between the one- and two-TEA groups (p = 0.148). The mean transfusion rate was higher in the placebo group than in the other two groups (22% versus 3.8% (p = 0.006) and 6.1% (p = 0.041), respectively) and there was no statistically significant difference in the mean transfusion rate between the one- and two-TEA groups (p = 0.672). Only one patient, in the two-dose group, had a radiologically confirmed deep venous thrombosis. Our prospective randomised controlled study showed that one intra-operative injection of TEA is effective for blood conservation after minimally invasive TKR.
Kaohsiung Chang Gung Memorial Hospital Chang Gung University College of Medicine, 123 Ta Pei Road, Niao Sung District, Kaohsiung City, Kaohsiung 83301, Taiwan.
P-C
PC
Lin
C-H
CH
Hsu
C-C
CC
Huang
W-S
WS
Chen
J-W
JW
Wang
D000368:Aged; D000369:Aged, 80 and over; D000933:Antifibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D019645:Arthroplasty, Replacement, Knee / Q000009:adverse effects / Q000379:methods; D001803:Blood Transfusion; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006454:Hemoglobins / Q000378:metabolism; D006488:Hemostasis, Surgical / Q000379:methods; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D019060:Minimally Invasive Surgical Procedures / Q000009:adverse effects / Q000379:methods; D019990:Perioperative Care / Q000379:methods; D019106:Postoperative Hemorrhage / Q000209:etiology / Q000517:prevention & control*; D014148:Tranexamic Acid / Q000008:administration & dosage / Q000627:therapeutic use
D000933:Antifibrinolytic Agents; D006454:Hemoglobins; D014148:Tranexamic Acid